Fujian Haixi Pharmaceuticals Co., Ltd. Class H (2637) Price & Analysis

Fujian Haixi Pharmaceuticals Co., Ltd. engages in research and development, production, and sale of pharmaceutical products in China. The company offers drugs for oncology, ophthalmology, respiratory, digestion, cardiovascular, endocrine, and nervous systems, and inflammation. It also provides pharmaceuticals technical services. In addition, the company offers generic alternatives, such as Anbili, a generic of mosapride citrate tablets; Haihuitong 5mg/10mg and 5mg/20mg, a generic of amlodipine besilate and atorvastatin calcium tablets; Ruiantuo, a generic of cinacalcet hydrochloride tablets; and Saixifu, a generic of hydroxychloroquine sulfate tablets. Further, it provides Haibiping, a generic of valsartan and amlodipine tablets; Anyoufan, a generic of escitalopram oxalate tablets; Haikexi, a generic of valsartan tablets; Anfeiping, a generic of diclofenac sodium enteric-coated tablets; and Jishuning, a generic of cetirizine hydrochloride oral solution. Additionally, the company's pipeline includes C019199, a drug candidate targeting the modulation of the immunosuppressive tumor microenvironment for the treatment of advanced osteosarcoma, which has completed phase II clinical trials; HXP056, an oral small-molecule drug designed to treat retinopathy-related diseases, which has completed phase I clinical trial; HXP089, an oral small-molecule drug targeting glioblastoma multiforme; and HXP090, an oral small-molecule drug designed specifically targeting idiopathic pulmonary fibrosis. It sells its products through retail pharmacies, online pharmacies, and internet medical platforms. Fujian Haixi Pharmaceuticals Co., Ltd. was incorporated in 2012 and is based in Fuzhou, China.